Technical Analysis for VCYT - Veracyte, Inc.

Grade Last Price % Change Price Change
F 19.45 1.30% 0.25
VCYT closed up 1.3 percent on Friday, April 19, 2024, on 1.92 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 2
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Bullish Engulfing Bullish 1.30%
Lower Bollinger Band Walk Weakness 1.30%
New 52 Week Low Weakness 1.30%
Outside Day Range Expansion 1.30%
Lower Bollinger Band Touch Weakness 1.30%
Oversold Stochastic Weakness 1.30%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 21 hours ago
Rose Above Previous Day's High about 24 hours ago
Up 1% about 24 hours ago
Rose Above Previous Day's High 1 day ago
Outside Day 1 day ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Veracyte, Inc. Description

Veracyte, Inc. operates as a diagnostics company in the field of molecular cytology to enhance patient outcomes and lower healthcare costs. It provides Afirma Thyroid FNA Analysis, a solution that consists of its Gene Expression Classifier (GEC), which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. The company is also developing Afirma Malignant GEC test for rare forms of thyroid cancer or metastases to the thyroid that is intended to inform surgical strategy; and idiopathic pulmonary fibrosis and nodules suspicious products for lung cancer. It serves endocrinologists, radiologists, and head and neck specialists. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Telehealth Telemedicine Gene Expression Lung Cancer Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Thyroid Healthcare Costs Metastases Glands Surgeries Thyroid Cancer

Is VCYT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 30.52
52 Week Low 18.61
Average Volume 708,286
200-Day Moving Average 24.41
50-Day Moving Average 22.22
20-Day Moving Average 20.49
10-Day Moving Average 19.96
Average True Range 0.84
RSI (14) 37.50
ADX 27.08
+DI 14.97
-DI 31.06
Chandelier Exit (Long, 3 ATRs) 19.84
Chandelier Exit (Short, 3 ATRs) 21.12
Upper Bollinger Bands 22.34
Lower Bollinger Band 18.64
Percent B (%b) 0.22
BandWidth 18.09
MACD Line -0.84
MACD Signal Line -0.79
MACD Histogram -0.0592
Fundamentals Value
Market Cap 1.42 Billion
Num Shares 73 Million
EPS -0.69
Price-to-Earnings (P/E) Ratio -28.19
Price-to-Sales 5.44
Price-to-Book 1.77
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.23
Resistance 3 (R3) 20.17 19.86 20.10
Resistance 2 (R2) 19.86 19.66 19.89 20.06
Resistance 1 (R1) 19.65 19.54 19.76 19.71 20.01
Pivot Point 19.34 19.34 19.39 19.37 19.34
Support 1 (S1) 19.13 19.14 19.24 19.19 18.89
Support 2 (S2) 18.82 19.02 18.85 18.84
Support 3 (S3) 18.61 18.82 18.80
Support 4 (S4) 18.67